4D Molecular Therapeutics (NASDAQ:FDMT) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPS

4D Molecular Therapeutics (NASDAQ:FDMT) released its quarterly earnings data on Friday. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.10), Zacks reports.

4D Molecular Therapeutics Stock Performance

Shares of FDMT opened at $4.53 on Friday. 4D Molecular Therapeutics has a one year low of $4.20 and a one year high of $36.25. The stock has a market capitalization of $209.41 million, a price-to-earnings ratio of -1.59 and a beta of 2.81. The stock has a 50 day moving average price of $5.22 and a 200 day moving average price of $8.59.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on FDMT. Morgan Stanley cut their target price on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating on the stock in a research note on Monday, January 13th. Bank of America cut their target price on 4D Molecular Therapeutics from $79.00 to $46.00 and set a “buy” rating on the stock in a research note on Wednesday, December 18th. Leerink Partners dropped their price target on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a research note on Monday, January 13th. Chardan Capital dropped their price target on 4D Molecular Therapeutics from $39.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, February 11th. Finally, BMO Capital Markets lowered 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and dropped their price target for the stock from $40.00 to $15.00 in a research note on Monday, January 13th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $32.13.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.